HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Clinical trials for HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radioactive drug targets multiple cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new radioactive drug, [177Lu]Lu-NNS309, in adults with advanced pancreatic, lung, breast, or colorectal cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink t…
Matched conditions: HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
New targeted radiation therapy enters human testing for tough cancers
Disease control Recruiting nowThis early-stage study tests a new drug (177Lu-DFC413) that delivers radiation directly to cancer cells in adults with advanced solid tumors, including pancreatic, lung, breast, colorectal, and soft tissue cancers. The main goals are to check safety, find the right dose, and see …
Matched conditions: HR+/HER2- DUCTAL AND LOBULAR BREAST CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 19, 2026 11:48 UTC